Evidence map›Paper›PMID 32443980›Full record

ArticleMolecular cancer2020

Long noncoding RNA ZFAS1 promoting small nucleolar RNA-mediated 2'-O-methylation via NOP58 recruitment in colorectal cancer.

Huizhe Wu, Wenyan Qin, Senxu Lu, Xiufang Wang, Jing Zhang, Tong Sun, Xiaoyun Hu, Yalun Li, Qiuchen Chen, Yuanhe Wang and 4 more

Open access · goldAbstract read
In one paragraph

Article in Molecular cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 99 papers.

0numbers the graph read from it
0cells of the map it votes in
99citing papers in PubMed
7.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

99 citing papers in PubMed, 153 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Intronic polyadenylation-derived long noncoding RNA modulates nucleolar integrity and function.Proceedings of the National Academy of Sciences of the United States of America · 2026
    Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Chemically modified non-coding RNAs in cancer.Expert reviews in molecular medicine · 2025
    Review
  19. Article
  20. Article

39 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 1 institution in 1 country.

Huizhe WuDepartment of Pharmacology, School of Pharmacy, China Medical University, Shenyang, 110122, People's Republic of China.
Wenyan QinDepartment of Pharmacology, School of Pharmacy, China Medical University, Shenyang, 110122, People's Republic of China.
Senxu LuDepartment of Pharmacology, School of Pharmacy, China Medical University, Shenyang, 110122, People's Republic of China.
Xiufang WangDepartment of Pharmacology, School of Pharmacy, China Medical University, Shenyang, 110122, People's Republic of China.
Jing ZhangDepartment of Pharmacology, School of Pharmacy, China Medical University, Shenyang, 110122, People's Republic of China.
Tong SunDepartment of Pharmacology, School of Pharmacy, China Medical University, Shenyang, 110122, People's Republic of China.
Xiaoyun HuDepartment of Pharmacology, School of Pharmacy, China Medical University, Shenyang, 110122, People's Republic of China.
Yalun LiDepartment of Anorectal Surgery, First Hospital of China Medical University, Shenyang, 110001, People's Republic of China.
Qiuchen ChenDepartment of Pharmacology, School of Pharmacy, China Medical University, Shenyang, 110122, People's Republic of China.
Yuanhe WangDepartment of Medical Oncology, Cancer Hospital of China Medical University, Shenyang, 110042, People's Republic of China.
Haishan ZhaoDepartment of Pharmacology, School of Pharmacy, China Medical University, Shenyang, 110122, People's Republic of China.
Haiyan PiaoDepartment of Medical Oncology, Cancer Hospital of China Medical University, Shenyang, 110042, People's Republic of China.
Rui ZhangDepartment of Medical Oncology, Cancer Hospital of China Medical University, Shenyang, 110042, People's Republic of China. zhangrui@cancerhosp-ln-cmu.com.
Minjie WeiDepartment of Pharmacology, School of Pharmacy, China Medical University, Shenyang, 110122, People's Republic of China. mjwei@cmu.edu.cn.
China Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIncreasing evidence supports the role of small nucleolar RNAs (snoRNAs) and long non-coding RNAs (lncRNAs) as master gene regulators at the epigenetic modification level. However, the underlying mechanism of these functional ncRNAs in colorectal cancer (CRC) has not been well investigated.

methodsThe dysregulated expression profiling of lncRNAs-snoRNAs-mRNAs and their correlations and co-expression enrichment were assessed by GeneChip microarray analysis. The candidate lncRNAs, snoRNAs, and target genes were detected by in situ hybridization (ISH), RT-PCR, qPCR and immunofluorescence (IF) assays. The biological functions of these factors were investigated using in vitro and in vivo studies that included CCK8, trans-well, cell apoptosis, IF assay, western blot method, and the xenograft mice models. rRNA 2'-O-methylation (Me) activities were determined by the RTL-P assay and a novel double-stranded primer based on the single-stranded toehold (DPBST) assay. The underlying molecular mechanisms were explored by bioinformatics and RNA stability, RNA fluorescence ISH, RNA pull-down and translation inhibition assays.

resultsTo demonstrate the involvement of lncRNA and snoRNAs in 2'-O-Me modification during tumorigenesis, we uncovered a previously unreported mechanism linking the snoRNPs NOP58 regulated by ZFAS1 in control of SNORD12C, SNORD78 mediated rRNA 2'-O-Me activities in CRC initiation and development. Specifically, ZFAS1 exerts its oncogenic functions and significantly up-regulated accompanied by elevated NOP58, SNORD12C/78 expression in CRC cells and tissues. ZFAS1 knockdown suppressed CRC cell proliferation, migration, and increased cell apoptosis, and this inhibitory effect could be reversed by NOP58 overexpression in vitro and in vivo. Mechanistically, the NOP58 protein could be recognized by the specific motif (AAGA or CAGA) of ZFAS1. This event accelerates the assembly of SNORD12C/78 to allow for further guiding of 2'-O-Me at the corresponding Gm3878 and Gm4593 sites. Importantly, silencing SNORD12C or 78 reduced the rRNAs 2'-O-Me activities, which could be rescued by overexpression ZFAS1, and this subsequently inhibits the RNA stability and translation activity of their downstream targets (e.g., EIF4A3 and LAMC2).

conclusionThe novel ZFAS1-NOP58-SNORD12C/78-EIF4A3/LAMC2 signaling axis that functions in CRC tumorigenesis provides a better understanding regarding the role of lncRNA-snoRNP-mediated rRNAs 2'-O-Me activities for the prevention and treatment of CRC.

Indexed as

DNA MethylationAnimalsApoptosisBiomarkers, TumorCell ProliferationColorectal NeoplasmsGene Expression Regulation, NeoplasticHumansMiceMice, Inbred BALB CMice, NudeNuclear ProteinsRibonucleoproteins, Small NucleolarRNA, Long NoncodingRNA, Small NucleolarRNA StabilityBiomarkers, TumorNOP58 protein, humanNuclear ProteinsRibonucleoproteins, Small NucleolarRNA, Long NoncodingRNA, Small NucleolarZFAS1 long non-coding RNA, human2′-O-methylation (2′-O-me)Colorectal cancer (CRC)NOP58SNORD12CSNORD78ZFAS1

Identifiers

PMID32443980
PMCPMC7243338
OpenAlexW3028534070

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.